# Data Sheet (Cat.No.T21729)

TargetMol

## (±)-Lisofylline

### Chemical Properties



CAS No. : 6493-06-7

Formula: C13H20N4O3

Molecular Weight: 280.32

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

### Biological Description

| | |
|---|---|
| Description | (±)-Lisofylline is an enantiomer-specific, alkyl-substituted methylxanthine, which has specific and potent activity in down-regulating leukocyte activation. (±)-Lisofylline is an anti-inflammatory agent. |
| Targets(IC50) | Others,Interleukin |
| In vivo | (±)-Lisofylline improves survival in this model of hemorrhagic shock in Sprague-Dawley rats[1]. |

### Solubility Information

| | |
|---|---|
| Solubility | DMSO: 4.8 mg/mL (17.12 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (3.57 mM),Sonication is recommended.<br>*Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.* |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 3.5674 mL | 17.8368 mL | 35.6735 mL |
| 5 mM | 0.7135 mL | 3.5674 mL | 7.1347 mL |
| 10 mM | 0.3567 mL | 1.7837 mL | 3.5674 mL |
| 50 mM | 0.0713 mL | 0.3567 mL | 0.7135 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Waxman K, et al. Lisofylline decreases white cell adhesiveness and improves survival after experimental hemorrhagic shock. Crit Care Med. 1996 Oct;24(10):1724-8.

Ali M, et al. Lisofylline mitigates cardiac inflammation in a mouse model of obesity through improving insulin secretion and activating cardiac AMPK signaling pathway. Cytokine. 2021 Feb;138:155398.